The Business Research Company Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

Blood clotting disorders can be inherited or acquired. Some types cause excessive bleeding, while others cause excessive ...

“Gene therapy for hemophilia A with the use of lentiviral vector-transduced autologous HSCs resulted in stable factor VIII ...

In December 2014, five years before Spark was acquired by Swiss drug giant Roche ... payment from Pfizer in 2015 when the experimental hemophilia B gene therapy entered Phase 1 clinical testing.

Pfizer had acquired the asset in the Bamboo acquisition ... linked to the development of a gene therapy candidate targeting hemophilia A. This decision came months after Pfizer announced positive ...

Pfizer will focus on Hympavzi, the first U.S.-approved anti-TFPI for hemophilia. Beqvez was FDA-approved in April 2024 but saw low adoption from patients. Get 5 stock picks identified before their ...

The gene therapy biotech was later acquired by Roche, which has had its own struggles with the modality in hemophilia. With its Sangamo partnership terminated and Beqvez being discontinued ...

Today [21 February], bluebird bio, a biotech that has two approved gene therapies in blood disorders, announced it will be acquired by two global investment firms to secure its future. This news came ...

Pfizer will no longer develop and commercialize its hemophilia B gene therapy Beqvez across all of its global markets, according to multiple media reports Thursday. In a statement to Nikkei Asia, the ...

But, as recent setbacks have shown, researchers and drugmakers still face major challenges. The pioneering gene therapy developer will be acquired by investment firms Carlyle Group and SK Capital for ...

Bengaluru’s iconic MTR Foods is reportedly in advanced discussions to be acquired by ITC Ltd, according to a report by The Mint. This move is seen as ITC’s strategic effort to strengthen its ...

in children and adults with hemophilia A. Previously known as BIVV001, it’s administered via an into-the-vein (intravenous) injection. It was originally developed by Bioverativ, but the company was ...